Imugene (AU:IMU)

ASX:IMU

IMU

Imugene

RESEARCH TOOLSreports

Imugene (IMU) Price & Analysis

145 Followers

IMU Stock Chart & Stats

AU$0.33

>-AU$0.01(-2.22%)

At close: Jan 09 4:00 PM EST

AU$0.33

>-AU$0.01(-2.22%)

Day’s Range― - ―

52-Week RangeAU$0.13 - AU$1.02

Previous CloseN/A

Volume11.90M

Average Volume (3M)877.83K

Market Cap

AU$51.77M

Enterprise ValueAU$42.65M

Total Cash (Recent Filing)AU$14.14M

Total Debt (Recent Filing)AU$5.02M

Price to Earnings (P/E)―

Beta2.10

Next Earnings

Aug 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding357,010,350

10 Day Avg. Volume850,615

30 Day Avg. Volume877,834

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)2.15

Price to Sales (P/S)21.99

P/FCF Ratio-1.07

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.18

Revenue Forecast (FY)AU$5.00M

Bulls Say, Bears Say

Bulls Say

Clinical-stage Pipeline BreadthA diversified clinical-stage pipeline (CF33 oncolytic programs, PD1-Vaxx, HER-Vaxx) spreads development risk across modalities and indications. Multiple assets increase chances of a value-inflecting outcome, and support licensing or partnership options that underpin longer-term strategic optionality.

Conservative Capital StructureLow leverage (debt/equity 0.24) and a moderate equity ratio imply limited financial fixed-cost pressure from interest. This conservative structure provides flexibility to fund R&D through cycles, reduces solvency risk, and supports execution of multi-stage clinical programs without excessive debt servicing.

Free Cash Flow Relative To Net IncomeA free cash flow to net income ratio above 1.0 suggests free cash flow exceeds accounting losses, indicating that non-cash charges or timing are not destroying cash. When sustained, this can help fund trials and operations and reduces immediate dependence on equity raises for near-term program activity.

Bears Say

Severe Revenue DeclineA massive revenue contraction (-338.95%) is a structural red flag: it erodes operating scale, weakens partner negotiation leverage, and undermines the company’s ability to absorb fixed R&D and G&A costs. Sustained declines increase reliance on external financing to progress programs.

Negative Return On EquityA deeply negative ROE (-153.27%) signals persistent destruction of shareholder capital and inability to generate returns from invested equity. Over time this impairs investor confidence, makes long-term capital raising more dilutive or costly, and reflects entrenched operational losses.

Weak Operating Cash GenerationNegative operating cash flow indicates the business is consuming cash to run operations and trials. This structural cash burn forces reliance on external funding, increases dilution or debt risk, and constrains the company’s ability to sustain or expand clinical programs without additional capital.

Imugene News

Imugene Issues Additional Unquoted Options as Part of Ongoing Capital Management

The latest announcement is out from Imugene ( ($AU:IMU) ). Imugene Limited has notified the market of the...

1d ago

Imugene Seeks ASX Quotation for Shares Issued on Option Conversions

Imugene ( ($AU:IMU) ) has provided an announcement. Imugene Limited has applied to the ASX for quotation of...

2d ago

Imugene’s Lead CAR T Therapy Azer-cel Wins Prestigious ASCO 2026 Oral Slot

Imugene ( ($AU:IMU) ) has provided an update. Imugene announced that new data from its lead CAR T...

2d ago

Imugene’s PD1-Vaxx Lung Cancer Trial Ends Early: What Investors Should Know

Imugene Ltd ($IUGNF) announced an update on their ongoing clinical study. The IMU-201 (PD1-Vaxx) IMPrinter trial, officially titled...

9d ago

IUGNF

Imugene calls hybrid Extraordinary General Meeting with expanded online access

The latest update is out from Imugene ( ($AU:IMU) ). Imugene Limited has called an Extraordinary General Meeting...

11d ago

Imugene Issues 35.4 Million New Shares in ASX Placement

Imugene ( ($AU:IMU) ) has provided an announcement. Imugene Limited has issued 35,445,999 fully paid ordinary shares at...

15d ago

Imugene Seeks ASX Quotation for 35.4 Million New Shares

The latest update is out from Imugene ( ($AU:IMU) ). Imugene Limited has applied for quotation on the...

15d ago

Imugene Issues Additional Unquoted Options Under Existing Equity Arrangements

The latest announcement is out from Imugene ( ($AU:IMU) ). Imugene Limited has notified the market of the...

15d ago

Imugene Seeks ASX Quotation for Additional Ordinary Shares

Imugene ( ($AU:IMU) ) has provided an announcement. Imugene Limited has applied to the Australian Securities Exchange for...

15d ago

Imugene Clarifies Scale-Back Terms on Securities Purchase Plan

Imugene ( ($AU:IMU) ) just unveiled an announcement. Imugene Limited has updated its Appendix 3B filing for a...

15d ago

IMU FAQ

What was Imugene’s price range in the past 12 months?

Imugene lowest share price was AU$0.13 and its highest was AU$1.02 in the past 12 months.

What is Imugene’s market cap?

Imugene’s market cap is AU$51.77M.

When is Imugene’s upcoming earnings report date?

Imugene’s upcoming earnings report date is Aug 28, 2026 which is in 147 days.

How were Imugene’s earnings last quarter?

Imugene released its earnings results on Feb 25, 2026. The company reported -AU$0.13 earnings per share for the quarter, beating the consensus estimate of -AU$0.34 by AU$0.21.

Is Imugene overvalued?

According to Wall Street analysts Imugene’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Imugene pay dividends?

Imugene does not currently pay dividends.

What is Imugene’s EPS estimate?

Imugene’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Imugene have?

Imugene has 357,010,350 shares outstanding.

What happened to Imugene’s price movement after its last earnings report?

Imugene reported an EPS of -AU$0.13 in its last earnings report, beating expectations of -AU$0.34. Following the earnings report the stock price went down -5.882%.

Which hedge fund is a major shareholder of Imugene?

Currently, no hedge funds are holding shares in AU:IMU

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Imugene Stock Smart Score

Neutral

Fundamentals

Return on Equity

-134.65%

Trailing 12-Months

Asset Growth

-39.73%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Imugene

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.